Salmi AA - Search Results

1

MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.

Vallittu AM, Erälinna JP, Ilonen J, Salmi AA, Waris M. Vallittu AM, et al. Among authors: salmi aa. Acta Neurol Scand. 2008 Jul;118(1):12-7. doi: 10.1111/j.1600-0404.2007.00968.x. Epub 2007 Dec 13. Acta Neurol Scand. 2008. PMID: 18081914 Clinical Trial.

2

Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.

Oikonen M, Laaksonen M, Aalto V, Ilonen J, Salonen R, Erälinna JP, Panelius M, Salmi A. Oikonen M, et al. Mult Scler. 2011 Jun;17(6):672-80. doi: 10.1177/1352458510394397. Epub 2011 Jan 6. Mult Scler. 2011. PMID: 21212088

3

Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.

Peltoniemi J, Broberg EK, Halenius A, Setala N, Eralinna JP, Salmi AA, Roytta M, Hukkanen V. Peltoniemi J, et al. Among authors: salmi aa. Clin Exp Immunol. 2004 Aug;137(2):305-12. doi: 10.1111/j.1365-2249.2004.02528.x. Clin Exp Immunol. 2004. PMID: 15270847 Free PMC article.

4

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A, Erälinna JP; Finnish Beta-Interferon Study Group. Vallittu AM, et al. Neurology. 2002 Jun 25;58(12):1786-90. doi: 10.1212/wnl.58.12.1786. Neurology. 2002. PMID: 12084878

5

MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.

Vallittu AM, Salmi AA, Erälinna JP; Finnish Beta-Interferon Study Group. Vallittu AM, et al. Among authors: salmi aa. Neurol Sci. 2006 Feb;26(6):438-43. doi: 10.1007/s10072-006-0529-7. Neurol Sci. 2006. PMID: 16601938 Clinical Trial.

6

Low copy number detection of herpes simplex virus type 1 mRNA and mouse Th1 type cytokine mRNAs by Light Cycler quantitative real-time PCR.

Broberg EK, Nygårdas M, Salmi AA, Hukkanen V. Broberg EK, et al. Among authors: salmi aa. J Virol Methods. 2003 Sep;112(1-2):53-65. doi: 10.1016/s0166-0934(03)00191-5. J Virol Methods. 2003. PMID: 12951213

7

IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis.

Broberg EK, Salmi AA, Hukkanen V. Broberg EK, et al. Among authors: salmi aa. Neurosci Lett. 2004 Jul 8;364(3):173-8. doi: 10.1016/j.neulet.2004.04.059. Neurosci Lett. 2004. PMID: 15196670

8

[The clinical picture of MS disease is now more complete].

Panelius M, Salmi AA. Panelius M, et al. Among authors: salmi aa. Duodecim. 1992;108(1):73-5. Duodecim. 1992. PMID: 1365986 Review. Finnish. No abstract available.

9

The significance of the 3'-nontranslated region and E2 amino acid mutations in the virulence of Semliki Forest virus in mice.

Santagati MG, Määttä JA, Röyttä M, Salmi AA, Hinkkanen AE. Santagati MG, et al. Among authors: salmi aa. Virology. 1998 Mar 30;243(1):66-77. doi: 10.1006/viro.1998.9031. Virology. 1998. PMID: 9527916

10

Semliki Forest virus infection leads to increased expression of adhesion molecules on splenic T-cells and on brain vascular endothelium.

Soilu-Hänninen M, Röyttä M, Salmi AA, Salonen R. Soilu-Hänninen M, et al. Among authors: salmi aa. J Neurovirol. 1997 Oct;3(5):350-60. doi: 10.3109/13550289709030749. J Neurovirol. 1997. PMID: 9372456

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results